68825-29-6

Usage

Uses

Used in Organic Synthesis:
TBPA is utilized as a building block in organic synthesis for creating a range of phenothiazine derivatives. Its structural properties allow for the development of complex molecules that can be further explored for their chemical and biological properties.
Used in Pharmaceutical Research:
In pharmaceutical research, TBPA is employed as a precursor for the synthesis of phenothiazine-based drugs. These derivatives have been studied for their potential therapeutic applications, including antipsychotic, anti-inflammatory, and antihistaminic properties, making TBPA a valuable component in the discovery and development of new medications.
Used in Drug Development:
TBPA plays a crucial role in drug development as it enables the creation of phenothiazine derivatives with diverse pharmacological profiles. Its versatility in chemical reactions facilitates the design and synthesis of novel compounds that can be optimized for specific therapeutic targets, contributing to the advancement of medicinal chemistry.

Upstream product

• 92-84-2 10H-phenothiazine 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 125096-15-3 2-(10H-phenothiazin-10-yl)acetic acid hydrazide 
• 860017-21-6 10-{[5'-benzylideneacetylamino-(1',3',4'-oxadiazol-2'-yl)]methyl}phenothiazine 
• 860017-27-2 3-(2-methoxy-phenyl)-N-(5-phenothiazin-10-ylmethyl-[1,3,4]oxadiazol-2-yl)-acrylamide 
• 860017-26-1 3-(4-hydroxy-phenyl)-N-(5-phenothiazin-10-ylmethyl-[1,3,4]oxadiazol-2-yl)-acrylamide 
• 860017-23-8 3-(4-methoxy-phenyl)-N-(5-phenothiazin-10-ylmethyl-[1,3,4]oxadiazol-2-yl)-acrylamide 
• 860017-25-0 3-(4-dimethylamino-phenyl)-N-(5-phenothiazin-10-ylmethyl-[1,3,4]oxadiazol-2-yl)-acrylamide 
• 860017-24-9 3-(4-hydroxy-3-methoxy-phenyl)-N-(5-phenothiazin-10-ylmethyl-[1,3,4]oxadiazol-2-yl)-acrylamide 
• 92-84-2 10H-phenothiazine 
• 1207-72-3 N-methylphenothiazine 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline or thioxanthenone (or similar) structure which function as autophagy inhibitors and/or histone deactylase inhibitors, and their use as therapeutics for the treatment of conditions characterized with aberrant autophagy activity and/or aberrant HDAC activity (e.g., cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, aging, heart disease, rheumatoid arthritis, infectious diseases, conditions and symptoms caused by a viral infection (e.g., COVID-19)).

Synthesis of Novel β-Lactams from Phenothiazin-10-ylacetic Acid

The first synthesis of 3-phenothiazine-β-lactams is herein reported. Thirteen new derivatives of β-lactams were synthesized using various Schiff bases and (phenothiazin-10-yl)acetic acid, which in turn was prepared starting from phenothiazine. The sole product of the Staudinger ketene–imine [2?+?2] cycloaddition reaction is the trans-β-lactam. All the synthesized compounds were characterized by elemental analyses and spectral (IR, 1H-NMR, and 13C-NMR) data.

Synthesis and antioxidant evaluation of novel phenothiazine linked substitutedbenzylideneamino-1,2,4-triazole derivatives

A series of novel 5-((10H-phenothiazin-10yl)methyl)-4-(substitutedbenzylideneamino)-4H-1,2,4-triazole-3-thiol derivatives (6a-i) have been synthesized from compound (1) through a multi-step reaction. The key intermediate (5) afforded a series of title com

INHIBITORS OF MALT1 PROTEASE

The present invention relates to compounds which are inhibitors of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALTl) and to their use in therapy, in particular in the treatment or prevention of a disease or disorder which is treatable by an inhibitor of a paracaspase. The present invention also relates to pharmaceutical compositions containing such compounds.

Phenothiazine as an aromatic capping group to construct a short peptide-based 'super gelator'

We report a 'super-gelator' of a short peptide capped with phenothiazine acetic acid.

Synthesis and anti-inflammatory activity of fused 1,2,4-triazolo-[3,4-b] [1,3,4]thiadiazole derivatives of phenothiazine

A new series of 10-((6-(substitutedphenyl)-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazol-3-yl)methyl)-10H-phenothiazine derivatives (7a-k) moiety was prepared using intermediate compound 5-((10H-phenothiazin-10-yl)methyl)-4-amino-4H-1,2, 4-triazole-3-thiol (5). The structures of newly synthesized compounds were confirmed on the basis of their 1H NMR, 13C NMR, LCMS mass, FT-IR and elemental analysis data results. All the compounds were screened for their significant anti-inflammatory activity of inhibition in paw oedema at 3h and 5h respectively, compared to the standard drug indomethacin. The Compounds 7k and 7d showed potent activity, while compounds 7g, 7b, 7j, 7i and 7c exhibited significant activity when compared to the standard drug, due to the presence of mild electron withdrawing groups such as difluoro, fluorine, chlorofluoro, nitro and chlorine derivatives which are attached to the benzene rings. 2013 Bentham Science Publishers.

New farnesyltransferase inhibitors in the phenothiazine series

The biological screening of the chemical library of our Organic Chemistry Department, carried out on an automated fluorescence-based FTase assay, allowed us to discover that a phenothiazine derivative (1d) was an inhibitor of farnesyltransferase. Three new series of human farnesyltransferase inhibitors, based on a phenothiazine scaffold, were synthesized with protein farnesyltransferase inhibition potencies in the low micromolar range. Ester derivative 9d was the most active compound in these series. Four synthesized compounds were evaluated for their antiproliferative activity on a NCI-60 cancer cell line panel. The modest results obtained in this preliminary investigation showed that mixing the phenothiazine and the 1,2,3-triazole motif in the structure of a single compound can lead to new scaffolds in the field of farnesyltransferase inhibitors.

Design, synthesis, and evaluation of efflux substrate-metal chelator conjugates as potential antimicrobial agents

Maintaining a proper balance of metal concentrations is critical to the survival of bacteria. We have designed and synthesized a series of conjugates of metal chelators and efflux transporter substrates aimed at disrupting bacterial metal homeostasis to a

Synthesis of newer indolyl/phenothiazinyl substituted 2-oxo/thiobarbituric acid derivatives as potent anticonvulsant agents

2-Amino-5-(heteroarylmethylene)-1,3,4-oxadiazoles/thiadiazoles 7-10 were synthesized by cyclisation of 1-(heteroarylacetyl)semicarbazides/thiosemicarbazides 3-6. 5-(2′-Heteroarylmethylene-5′-aminomethylene-1′, 3′, 4′-oxadiazol-2′-yl/thiadiazol-2′-yl)-2-oxo/thiobarbituric acids 11-18 were synthesized by condensation of compounds 7-10 at the 5th position of 2-oxo/thiobarbituric acids. The newly synthesized compounds showed anticonvulsant activity ranging from 50-90% (seizures protection). Compound 18 (5-(2′-phenothiazinylmethylene-5′- aminomethylene-1′3′,4′-thiadiazol-2′-yl)-2- thiobarbituric acid) showed maximum activity being more potent than the reference drug phenytoin sodium (CAS 630-93-3).

Synthesis of some new phenothiazinothiadiazoles and their azetidinones: Antifungal agents

A series of 2-arylideneamino-5-(N10-phenothiazinomethyl)-1,3,4-thiadiazoles 4a-k have been synthesized via condensation of 2-amino-5-(N10-phenothiazinomethyl)-1,3,4-thiadiazole 3 with various carbonyl compounds.Cycloaddition of acety